Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider's stock worth $1,077,270,000 after buying an additional 38,690,577 shares in the last quarter.
Several other equities analysts also recently issued reports on the company. Bank of Montreal Can boosted its position in shares of Boston Scientific Corporation by 12.9% during the second quarter. The firm owned 11,909 shares of the medical equipment provider's stock after selling 3,865 shares during the quarter.
As of the end of the quarter American International Group Inc had sold 21,527 shares trimming its stake by 5.0%. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider's stock valued at $2,596,181,000 after buying an additional 2,522,556 shares during the period. Analysts are turning out to be more optimistic than before, with 18 of analysts who cover Boston Scientific Corporation (NYSE:BSX) advice adding it to buy candidate list. First Republic Investment Management Inc. now owns 294,625 shares of the company's stock worth $5,541,000 after buying an additional 122,466 shares during the last quarter. Louisiana State Employees Retirement System now owns 84,900 shares of the medical equipment provider's stock worth $2,353,000 after purchasing an additional 1,100 shares during the last quarter.
In related news, SVP Maulik Nanavaty sold 57,031 shares of the company's stock in a transaction on Thursday, August 31st. The total value of its holdings increased 14.0%. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 10,104 shares of the stock in a transaction that occurred on Friday, September 1st. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a specific period of time. Following the completion of the transaction, the executive vice president now owns 164,681 shares of the company's stock, valued at approximately $4,647,297.82. The disclosure for this sale can be found here.
Netflix notes "59% of Aussies are Watching Netflix in public"
In a new survey conducted by Netflix (via SurveyMonkey), about 37% of Netflix's U.S. subscribers said they binge-watched while at work.
Shares of Boston Scientific Corporation (BSX) traded up $0.09 during trading on Tuesday, reaching $28.45. Insiders have sold a total of 508,864 shares of company stock worth $14,581,669 over the last 90 days. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93. Boston Scientific Corp now has a P/E ratio of 46.71 and the market cap is 38.88B. Boston Scientific Corporation (NYSE:BSX) has a 20-Day average volume of 6.98 Million. Boston Scientific Corporation's quarterly revenue was up 5.6% compared to the same quarter last year. research analysts anticipate that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.
Price-to-free-cash-flow (P/FCF) of 49.29 gives an overview of the equity valuation for Boston Scientific Corporation. The firm's revenue was up 5.6% on a year-over-year basis. analysts predict that Boston Scientific Corporation will post 1.25 earnings per share for the current year. If you are viewing this report on another site, it was stolen and reposted in violation of United States and global trademark and copyright law. The correct version of this news story can be read at https://weekherald.com/2017/11/14/toronto-dominion-bank-buys-56539-shares-of-boston-scientific-corporation-bsx.html.
Following recent price action, Boston Scientific Corp (BSX) shares have been identified trading above the Chikou. The count of Hold ratings in that period was 1. BMO Capital Markets upped their price objective on Boston Scientific Corporation from $30.00 to $32.00 and gave the company an "outperform" rating in a research note on Friday, October 27th. On October 31, 2017 SunTrust Banks updated guidance on BSX with a rating of "Buy" and projecting a price target of $34.00. (NYSE:BSX) from a buy rating to a hold rating in a research note issued to investors on Monday morning.
October 13 investment analysts at BMO Capital Markets held the stock rating at "Buy" targeting a price of $30.00.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
- Venezuela-finally and officially-defaulted on its bonds
- Ikea UK sales boom
- Wenger speaks on Manchester City unbeaten run
- Market turns choppy, trades in loss on inflation fears
- Rohr Disappointed Over Messi's Absence Against Nigeria
- 'Does India need bullet train?', asks Quora user, Piyush Goyal responds
- Sam Mendes no longer directing Disney's live-action Pinocchio
- Aronimink Golf Club lands 2027 PGA Championship, 2020 KPMG Women's PGA
- Gabriel Batistuta: Lionel Messi taking my Argentina record annoyed me
- Vidya Balan On Why Indian Culture Considers Sex Taboo